Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...